drugset / Trial / NCT01745094
A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the safety and efficacy of mirabegron as add-on therapy in patients with OAB treated with solifenacin.
Timeline
- Start
- 2012-10-01
- Primary completion
- 2013-07-23
- Completion
- 2013-07-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirabegron | Other / unclassified | 25 mg | Oral |
| Subject | Mirabegron | Other / unclassified | 50 mg | Oral |
| Background | Solifenacin | Small molecule | 2.5 mg | Oral |
| Background | Solifenacin | Small molecule | 5 mg | Oral |